A polymorphism in NFKB1 is associated with improved effect of interferon-α maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support

Por Vangsted, Annette J., Klausen, Tobias W., Gimsing, Peter, Andersen, Niels F., Abildgaard, Niels, Gregersen, Henrik, Vogel, Ulla
Publicado em 2009

Serum galectin-1 in patients with multiple myeloma: associations with survival, angiogenesis, and biomarkers of macrophage activation

Por Andersen, Morten Nørgaard, Ludvigsen, Maja, Abildgaard, Niels, Petruskevicius, Irma, Hjortebjerg, Rikke, Bjerre, Mette, Honoré, Bent, Møller, Holger J, Andersen, Niels F
Publicado no Onco Targets Ther (2017)

No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma

Por Vangsted, Annette J, Søeby, Karen, Klausen, Tobias W, Abildgaard, Niels, Andersen, Niels F, Gimsing, Peter, Gregersen, Henrik, Vogel, Ulla, Werge, Thomas, Rasmussen, Henrik B
Publicado em 2010